Cancer Immunology, Immunotherapy

, Volume 48, Issue 12, pp 661–672 | Cite as

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens

  • Craig L. Slingluff Jr.
  • Teresa A. Colella
  • Lee Thompson
  • D. David Graham
  • Jonathan C.A. Skipper
  • Jennifer Caldwell
  • Larry Brinckerhoff
  • David J. Kittlesen
  • Donna H. Deacon
  • Correen Oei
  • Nancy L. Harthun
  • Eric L. Huczko
  • Donald F. Hunt
  • Tim L. Darrow
  • Victor H. Engelhard
ORIGINAL ARTICLE

Abstract

Melanoma-reactive HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) lines generated in vitro lyse autologous and HLA-matched allogeneic melanoma cells and recognize multiple shared peptide antigens from tyrosinase, MART-1, and Pmel17/gp100. However, a subset of melanomas fail to be lysed by these T cells. In the present report, four different HLA-A*0201+ melanoma cell lines not lysed by melanoma-reactive allogeneic CTL have been evaluated in detail. All four are deficient in expression of the melanocytic differentiation proteins (MDP) tyrosinase, Pmel17/gp100, gp75/trp-1, and MART-1/Melan-A. This concordant loss of multiple MDP explains their resistance to lysis by melanoma-reactive allogeneic CTL and confirms that a subset of melanomas may be resistant to tumor vaccines directed against multiple MDP-derived epitopes. All four melanoma lines expressed normal levels of HLA-A*0201, and all were susceptible to lysis by xenoreactive-peptide-dependent HLA-A*0201-specific CTL clones, indicating that none had identifiable defects in antigen-processing pathways. Despite the lack of shared MDP-derived antigens, one of these MDP-negative melanomas, DM331, stimulated an effective autologous CTL response in vitro, which was restricted to autologous tumor reactivity. MHC-associated peptides isolated by immunoaffinity chromatography from HLA-A1 and HLA-A2 molecules of DM331 tumor cells included at least three peptide epitopes recognized by DM331 CTL and restricted by HLA-A1 or by HLA-A*0201. Recognition of these CTL epitopes cannot be explained by defined, shared melanoma antigens; instead, unique or undefined antigens must be responsible for the autologous-cell-specific anti-melanoma response. These findings suggest that immunotherapy directed against shared melanoma antigens should be supplemented with immunotherapy directed against unique antigens or other undefined antigens, especially in patients whose tumors do not express MDP.

Keywords Melanoma Antigens Cytotoxic T lymphocytes Human Immunotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • Craig L. Slingluff Jr.
    • 1
  • Teresa A. Colella
    • 2
  • Lee Thompson
    • 1
  • D. David Graham
    • 1
  • Jonathan C.A. Skipper
    • 2
  • Jennifer Caldwell
    • 3
  • Larry Brinckerhoff
    • 1
  • David J. Kittlesen
    • 1
  • Donna H. Deacon
    • 1
  • Correen Oei
    • 4
  • Nancy L. Harthun
    • 1
  • Eric L. Huczko
  • Donald F. Hunt
    • 3
  • Tim L. Darrow
    • 4
  • Victor H. Engelhard
  1. 1.Department of Surgery, University of Virginia, P.O. Box 10005, Charlottesville, VA 22906, USA e-mail: cls8h@avery.med.virginia.edu Tel.: +1-804-924-1505 Fax: +1-804-243-6844US
  2. 2.Department of Microbiology, University of Virginia, Charlottesville, VA 22906, USAUS
  3. 3.Department of Chemistry, University of Virginia, Charlottesville, VA 22906, USAUS
  4. 4.Department of Surgery, Duke University, Durham, NC 27710, USAUS

Personalised recommendations